Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | JAK3 A572V |
| Therapy | Tofacitinib |
| Indication/Tumor Type | mature T-cell and NK-cell lymphoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| JAK3 A572V | mature T-cell and NK-cell lymphoma | sensitive | Tofacitinib | Preclinical | Actionable | In a preclinical study, Xeljanz (tofacitinib), a pan-JAK inhibitor, reduced cell viability and increased apoptosis in a JAK3 A572V mutant natural killer/T-cell lymphoma cell line (PMID: 22705984). | 22705984 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22705984) | Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. | Full reference... |